Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 8/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13382984 | 1.00 | TK1 (0.40) | TK1HPGDRNASE1 | |
| SCHEMBL13383018 | 0.93 | TK1 (0.37) | TK1HPGDRNASE1 | |
| SCHEMBL13382988 | 0.89 | TK1 (0.41) | TK1HPGDRNASE1 | |
| SCHEMBL3274020 | 0.89 | TK1 (0.41) | TK1HPGDRNASE1 | |
| SCHEMBL15013060 | 0.88 | TK1 (0.35) | TK1RNASE1 | |
| SCHEMBL30590055 | 0.86 | TK1 (0.40) | TK1HPGDRNASE1 | |
| SCHEMBL13382985 | 0.85 | TK1 (0.43) | TK1HPGD | |
| SCHEMBL3277507 | 0.82 | TK1 (0.38) | TK1HPGD | |
| SCHEMBL13383007 | 0.81 | TK1 (0.38) | TK1HPGDRNASE1 | |
| SCHEMBL15013049 | 0.81 | TK1 (0.34) | TK1RNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461124-B2 | Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines for the treatment of infections and cancer | CHATTOPADHYAYA JYOTI (SE) | 2013-06-11 | — | — | US | disclosed |
| US-20100087387-A1 | FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'-CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER | CHATTOPADHYAYA JYOTI | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087387-A1 | FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'-CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER | TYMS, NSUN2, RNMT | TK1 12/4885HPGD 4552/4885RNASE1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.